CAMBRIDGE, Mass.--(BUSINESS WIRE)--Seres Therapeutics Inc. (NASDAQ:MCRB), a leading microbiome therapeutics platform company, today reported first quarter 2016 financial results and provided an operational progress update.
“The first quarter was marked by strong progress extending our leadership position in the development of microbiome therapeutics,” said Roger Pomerantz, M.D., President, CEO and Chairman of Seres. “Our clinical-stage programs are advancing rapidly.
“The first quarter was marked by strong progress extending our leadership position in the development of microbiome therapeutics,” said Roger Pomerantz, M.D., President, CEO and Chairman of Seres. “Our clinical-stage programs are advancing rapidly.
